Corrigendum to “Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial” [Eur. Urol. 86 (2024) 552–562, (S0302283824025600), (10.1016/j.eururo.2024.08.021)]

Andrew J. Armstrong, Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad, Tomasz M. Beer, Jiwen Wu, Osvaldo Mirante, Michael J. Morris

    Résultats de recherche: Contribution à un journal!!Comment/debate

    Résumé

    The authors regret a minor data error in the reporting of best radiographic responses in Supplementary Table 5 in the Supplementary Material. The percentage of patients with an evaluable response who had progressive disease (PD) in the 'Increase' subgroup for best overall PSA decline from baseline in the 177Lu-PSMA-617 arm should be 31% not 40%. The number of patients with PD (n = 22) and the denominator (n = 71) remain correct. The data in the Table should therefore read as ‘22 (31)’ not ‘22 (40)’. The authors also note that the rows in this Table are slightly misaligned vertically but are presented in the correct order.[Figure presented] The authors would like to apologise for any inconvenience caused.

    langue originaleAnglais
    journalEuropean Urology
    Les DOIs
    étatAccepté/sous presse - 1 janv. 2025

    Contient cette citation